Drug Database
TO

tolterodine (Detrol LA / Detrusitol Neo / Detrusitol Retard)

✓ Approved

Pfizer, Inc. · CHRM1 · 小分子

什么是 tolterodine?

tolterodine 是一种小分子,由Pfizer, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Detrol LA, Detrusitol Neo, Detrusitol Retard
公司Pfizer, Inc.
药物类别小分子
分子靶点CHRM1, CHRM2, CHRM3, CHRM4
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

tolterodine 作用于 4 个分子靶点:

CHRM1cholinergic receptor muscarinic 1 (M1, HM1)
CHRM2cholinergic receptor muscarinic 2 (HM2)
CHRM3cholinergic receptor muscarinic 3 (HM3, PBS)
CHRM4cholinergic receptor muscarinic 4 (HM4, M4R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tolterodine 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Renal and urinary disordersHypertonic bladder✓ Approved
Renal and urinary disordersUrinary incontinence✓ Approved

相关研究文献

PubMedCanadian journal of physiology and pharmacology2026-11-20

Antimuscarinic medication use and risk of glaucoma in patients with overactive bladder: a literature review and disproportionality analysis using individual case safety reports from FAERS.

Sadeghi Hasti H, Lau Rinko R, Omrani Mohammad Ali M, Ahmadi Fatemeh F et al.

This study investigated the potential association between antimuscarinic medications and glaucoma by integrating evidence from a literature review with pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). A systematic search of MEDLINE and EMBASE through 15 July 2025 identified eight studies, one pooled analysis of two randomized controlled trials, five observational studies, and two case reports that collectively suggested an association between anticholinergic use and increased risk of glaucoma or elevated intraocular pressure. Concurrently, an active-comparator restricted disproportionality analysis of FAERS data (2004Q1-2023Q4) was conducted to compare glaucoma reports among users of oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, and trospium versus mirabegron. Adjusted reporting odds ratios (RORs) and information components (IC025) were calculated following READUS-PV guidelines. Compared with mirabegron, antimuscarinics demonstrated a higher reporting rate of glaucoma (adjusted ROR: 3.02; 95% CI: 2.03-4.50; IC025: 0.15), with tolterodine showing the strongest signal (adjusted ROR: 7.67; 95% CI: 4.90-12.02; IC025: 1.24), followed by darifenacin, fesoterodine, and solifenacin. No signals were observed for oxybutynin or trospium. These findings suggest that certain antimuscarinics, particularly tolterodine, darifenacin, and fesoterodine, may be associated with an increased risk of glaucoma and warrant further pharmacoepidemiologic investigation to confirm safety and inform prescribing decisions.

PMID 43061943
阅读全文 →
PubMedHorticulture research2026-11-20

quarTeT after 3 years: toolkit updates and community insights for telomere-to-telomere genome assembly.

Sun Jiarui J, Lin Yunzhi Y, Sun Guocheng G, Hong Xueying X et al.

Since its initial release in 2023, quarTeT has become a widely used toolkit for telomere-to-telomere (T2T) genome assembly and characterization. Here, we present a major update that improves all four quarTeT modules, including optional contig filtering in AssemblyMapper, a refactored join algorithm in GapFiller, enhanced telomere detection in TeloExplorer (TE), and support for holocentric chromosomes in CentroMiner (CM). The main program has also been upgraded with user-configurable multithreading, broader version compatibility, and simplified deployment via Bioconda, Docker, and Singularity. Over the past 3 years, quarTeT has been adopted by 150 research groups in 22 countries and applied to 185 species, including plants, animals, fungi, and one bacterium. These efforts have helped to produce and characterize T2T or near-T2T assemblies across diverse evolutionary lineages. Community usage analysis indicates that TE and CM are the most frequently used modules, whether together or alone, reflecting the central focus on telomeres and centromeres. Benchmarking shows a 13.8% runtime reduction over the original release and superior efficiency over specialized tools (CentIER and CentriVision) across six plant genomes, with competitive or better accuracy. Independent validation using CENH3 ChIP-seq covering diverse centromere types further confirms that quarTeT performs robustly and outperforms existing tools. Finally, we discuss remaining challenges and outline future directions, including machine learning-based centromere prediction, extended support for non-canonical centromere architectures, and the development of new completeness metrics beyond N50. The updated quarTeT toolkit is freely available at https://www.atcgn.com/quartet and https://github.com/aaranyue/quarTeT.

PMID 43061690
阅读全文 →
PubMedExpert opinion on pharmacotherapy2026-11-20

Pharmacological considerations in opioid use disorder treatment in pregnant and postpartum patients.

Jones Hendrée E HE, Serenska Alice A, Peyton Ellis Laura L

Untreated perinatal opioid use disorder (OUD) is a major contributor to maternal and infant morbidity and mortality, worsened by an often adulterated fentanyl-dominant drug supply. Medication for OUD (MOUD) is standard of care, yet evidence guiding selection, initiation, dosing, pain management, neonatal withdrawal, breastfeeding, and postpartum continuity is evolving. This narrative review with expert opinion synthesizes five years of literature, alongside foundational trials, on MOUD treatment across pregnancy, delivery, and the first postpartum year, prioritizing shared decision-making and trauma-responsive care. Topics include MOUD maternal dose and formulation, fentanyl-era induction, adulterant-complicated withdrawal, peripartum pain management, neonatal considerations, medication-specific breastfeeding, postpartum co-occurring mental health and MOUD access challenges, and long-term child outcomes. A PubMed, Embase, and ClinicalTrials.gov search (2020-2026) supplemented foundational sources. Treatment needs to center in trust, non-judgment, and shared decision-making. Extended-release buprenorphine is an emerging preferred option, especially for patients stabilized on buprenorphine, and buprenorphine-naloxone appears to be as good as, if not better than, buprenorphine alone. Withdrawal management must accommodate an increasingly adulterated drug supply, and breastfeeding is generally compatible with MOUD. Like all children, prenatally opioid-exposed children need nurturing care, developmental screening, and early intervention when indicated.

PMID 43061994
阅读全文 →
PubMedJournal of child and adolescent psychopharmacology2026-11-20

A Narrative Review of Myths and Misconceptions About Methylphenidate in the Treatment of Attention-Deficit/Hyperactivity Disorder.

Patel Maitri R MR, Hughes Jo A JA, Childress Ann C AC

Methylphenidate (MPH) has been a cornerstone of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy for more than 70 years, with robust evidence supporting its efficacy and tolerability across the patient lifespan. Despite this extensive evidence base, persistent myths and misconceptions among clinicians, patients, and caregivers continue to drive treatment hesitancy, premature discontinuation, and suboptimal prescribing practices. Our objective was to identify and critically appraise prevalent myths surrounding MPH use in ADHD that may adversely influence treatment decisions. Myths were identified based on clinical experience, discussions with prominent ADHD experts, and a literature search for relevant articles and guidelines. Evidence from the literature was reviewed and supplemented with clinical recommendations. Twelve common misconceptions about MPH were identified. These include misconceptions about interchangeability and dose equivalence between MPH formulations, treatment timing for continuous symptom control, endurance of drug onset- and offset-related side effects, and patient feelings as an indicator of drug effectiveness. Myths that MPH will always cause insomnia, increase anxiety and depression, stunt growth, have similar levels of abuse potential and side effects as other drugs, or worsen behavior in patients with autism spectrum disorder were also identified, as well as a common misconception that MPH is only effective in child and adolescent populations. Evidence gathered from systematic reviews, meta-analyses, clinical trials, pharmacokinetic studies, and clinical practice guidelines provided counterarguments to these concerns. MPH remains a well-studied, effective, and generally well-tolerated treatment for ADHD in children, adolescents, and adults. The diversity of available formulations, including novel delivery systems such as delayed-release/extended-release MPH and serdexmethylphenidate/dexmethylphenidate, allows for individualized treatment matched to patient needs and daily functional demands. Clinicians who understand evidence-based rebuttals to myths about MPH can improve prescribing decisions and patient/family counseling while reducing the burden of misinformation that contributes to the undertreatment of this highly prevalent neurodevelopmental disorder.

PMID 43061900
阅读全文 →
PubMedNucleic acids research2026-11-20

CovPDB 2.0: an expanded covalent protein-ligand interactome.

Feng Yue Y, Qaseem Ammar A, Pfäffle Simon P SP, Moumbock Aurélien F A AFA et al.

The rational design of covalently binding inhibitors to specifically block selected target proteins has become a common strategy in drug discovery. Such design is based on structural insights into how electrophilic ligands bind to nucleophilic residues. CovPDB v1.0 provided high-resolution cocrystal structures of biologically relevant covalent protein-ligand complexes curated from the Protein Data Bank. Here, we describe CovPDB v2.0, a substantially extended release that addresses three main limitations of the original resource. First, to reflect the numerous novel covalently binding ligands developed and structurally elucidated over the past 4 years, we have classified, annotated, and integrated these entries into the database. This expands the collection from ~2300 to ~6200 protein-ligand complexes, comprising ~3600 pre-reactive ligands, ~1300 target proteins, 119 warheads, and 27 reaction types. Second, we expanded the structural scope beyond experimental cocrystals by generating AlphaFold3 cofolding models for additional ~6800 covalent complexes for which we had experimental evidence for a covalent ligand binding. Third, we added ~7100 non-covalent complexes in which the binding-site cysteines are annotated with a predicted reactivity and ligandability scores. A redesigned web interface allows users to browse, filter, and cross-search experimental, modelled, and ligandable-cysteine entries. CovPDB 2.0 is freely accessible at https://www.pharmbioinf.uni-freiburg.de/covpdb.

PMID 43059369
阅读全文 →
PubMedCanadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC2026-11-20

Addressing unsafe pharmaceutical disposal in Canada: The need for mandatory extended producer responsibility.

Kraut Roni Y RY, Katz Mathew N MN, Campbell Norman R C NRC, Nakatsu Nicole N et al.

PMID 43062448
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tolterodine